Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Chem ; 63(5): 2688-2704, 2020 03 12.
Article in English | MEDLINE | ID: mdl-31951130

ABSTRACT

A novel series of C(3)-substituted piperdinylindoles were developed as nociceptin opioid receptor (NOP) partial agonists to explore a pharmacological hypothesis that NOP partial agonists would afford a dual pharmacological action of attenuating Parkinson's disease (PD) motor symptoms and development of levodopa-induced dyskinesias. SAR around the C-3 substituents investigated effects on NOP binding, intrinsic activity, and selectivity and showed that while the C(3)-substituted indoles are selective, high affinity NOP ligands, the steric, polar, and cationic nature of the C-3 substituents affected intrinsic activity to afford partial agonists with a range of efficacies. Compounds 4, 5, and 9 with agonist efficacies between 25% and 35% significantly attenuated motor deficits in the 6-OHDA-hemilesioned rat model of PD. Further, unlike NOP antagonists, which appear to worsen dyskinesia expression, these NOP partial agonists did not attenuate or worsen dyskinesia expression. The NOP partial agonists and their SAR reported here may be useful to develop nondopaminergic treatments for PD.


Subject(s)
Antiparkinson Agents/therapeutic use , Indoles/therapeutic use , Parkinson Disease/drug therapy , Receptors, Opioid/agonists , Animals , Antiparkinson Agents/chemistry , Antiparkinson Agents/pharmacokinetics , Caco-2 Cells , Disease Models, Animal , Humans , Indoles/chemistry , Indoles/pharmacokinetics , Male , Parkinson Disease/metabolism , Parkinson Disease/physiopathology , Piperidines/chemistry , Piperidines/pharmacokinetics , Piperidines/therapeutic use , Rats , Rats, Sprague-Dawley , Receptors, Opioid/metabolism , Structure-Activity Relationship , Nociceptin Receptor
2.
Eur J Pharmacol ; 793: 1-13, 2016 Dec 15.
Article in English | MEDLINE | ID: mdl-27780725

ABSTRACT

Nociceptin/Orphanin FQ (N/OFQ) regulates several biological functions via selective activation of the N/OFQ receptor (NOP). In this study novel nonpeptide NOP ligands were characterized in vitro in receptor binding and [35S]GTPγS stimulated binding in membranes of cells expressing human NOP and classical opioid receptors, calcium mobilization assay in cells coexpressing the receptors and chimeric G proteins, bioluminescence resonance energy transfer (BRET) based assay for studying NOP receptor interaction with G protein and arrestin, the electrically stimulated mouse vas deferens and the mouse colon bioassays. The action of the AT compounds were compared with standard NOP agonists (N/OFQ and Ro 65-6570) and the NOP selective antagonist SB-612111. AT compounds displayed high NOP affinity and behaved as NOP agonists in all the functional assays consistently showing the following rank order of potency AT-127≥AT-090≥AT-035>AT-004= AT-001. AT compounds behaved as NOP full agonists in the calcium mobilization and mouse colon assays and as partial agonists in the [35S]GTPγS and BRET assays. Interestingly AT-090 and AT-127, contrary to standard nonpeptide agonists that display G protein biased agonism, behaved as an unbiased agonists. AT-090 and AT-127 displayed higher NOP selectivity than Ro 65-6570 at native mouse receptors. AT-090 and AT-127 might be useful pharmacological tools for investigating the therapeutic potential of NOP partial agonists.


Subject(s)
Cycloheptanes/pharmacology , Piperidines/pharmacology , Receptors, Opioid/agonists , Recombinant Proteins/metabolism , Animals , CHO Cells , Colon/drug effects , Colon/metabolism , Cricetinae , Cricetulus , Cycloheptanes/metabolism , HEK293 Cells , Humans , Ligands , Male , Mice , Piperidines/metabolism , Receptors, Opioid/genetics , Receptors, Opioid/metabolism , Recombinant Proteins/genetics , Vas Deferens/drug effects , Vas Deferens/metabolism , Nociceptin Receptor
SELECTION OF CITATIONS
SEARCH DETAIL
...